Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM

Nurix Therapeutics, Inc.

Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.
83% ORR and 22.1-month median PFS in r/r CLL with median 4 prior lines; 600 mg dose aligned with regulators.
New tablet formulation for autoimmune; IND target 2026. Partnered IRAK4 (GS-6791, Phase 1) and STAT6 (IND-enabling).
NX-1607 Phase 1a showed immune activation; confirmed partial response in MSS CRC across 82 patients.
Pro forma cash $663.8M after $250M equity raise; added CCO and two new board members.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.